Membranous Nephropathy

Idiopathic Membranous Nephropathy
Paul M. Johnson
https://medicine.med.unc.edu/

Idiopathic Membranous Glomerulonephritis!
http://www.infoplex.northwestern.edu

Treatment of Idiopathic Membranous Nephropathy
Alexander Usorov, MD
http://medicine.med.nyu.edu

Glomerular diseases
http://www.meddean.luc.edu

MKSAP Review – Glomerular Diseases
Patrick Cunningham M.D.
http://medchiefs.bsd.uchicago.edu/

Renal Pathology
Greg Balko, MD
http://www.med.wright.edu

Glomerular  Disease and Glomerular  Case Studies
Arthur  S. Schneider, M.D.
http://cmspath.edu

Battling the B cell- New biologic therapies for Lupus
Jennifer  H. Anolik, MD, PhD
http://www.urmc.rochester.edu

Glomerulo-pathies
Dr. Vivo
http://www.ttuhsc.edu/

Renal Pathology Glomerular Disorders
http://student.ttuhsc.edu

HIV associated nephropathy
Oleg Rubin, MD
http://intmedweb.wfubmc.edu

Nephrology Board Review
Palak Parikh
https://medicine.med.unc.edu

Extrapulmonary Sarcoidosis
Darrell Laudate
https://medicine.med.unc.edu/

The Great Imitator
Eric Edwards, MD
http://www.med.unc.edu/

207 free full text published articles on Membranous Nephropathy
1. Espinosa-Hernández M, Ortega-Salas R, López-Andreu M, Gómez-Carrasco JM,Pérez-Sáez MJ, Pérez-Seoane C, Aljama-García P. C4d as a diagnostic tool inmembranous nephropathy. Nefrologia. 2012 May 14;32(3):295-9. doi:10.3265/Nefrologia.pre2012.Feb.11224. English, Spanish.
2. Hinkes B, Hilgers KF, Bolz HJ, Goppelt-Struebe M, Amann K, Nagl S, Bergmann C,Rascher W, Eckardt KU, Jacobi J. A complex microdeletion 17q12 phenotype in apatient with recurrent de novo membranous nephropathy. BMC Nephrol. 2012 May14;13(1):27. [Epub ahead of print]
3. Hofstra JM, Wetzels JF. Anti-PLA₂R antibodies in membranous nephropathy. readyfor routine clinical practice? Neth J Med. 2012 Apr;70(3):109-13. Review.
4. Tao JL, Liu LL, Wen YB, Gao RT, Li H, Li MX, Li XM, Li XW. Cyclosporinetreatment in idiopathic membranous nephropathy nephrotic syndrome in adults. aretrospective study spanning 15 years. Chin Med J (Engl). 2011Nov;124(21):3490-4.
5. Matsumoto H, Nagaoka Y, Okada T, Wada T, Gondo A, Esaki S, Hayashi A, Miyaoka Y, Nakao T. Triple therapy with single daily dose of cyclosporine in Japanesepatients with idiopathic membranous nephropathy. Intern Med. 2011;50(18):1905-10.Epub 2011 Sep 15.
6. Gupta A, Lal C, Bhowmik D. De novo membranous nephropathy after hematopoietic stem cell transplantation. Saudi J Kidney Dis Transpl. 2011 Sep;22(5):1035-6.
7. Makker SP, Tramontano A. Idiopathic membranous nephropathy. an autoimmunedisease. Semin Nephrol. 2011 Jul;31(4):333-40. Review.
8. Cattran DC, Reich HN, Kim SJ, Troyanov S. Have we changed the outcome inmembranous nephropathy? A propensity study on the role of immunosuppressivetherapy. Clin J Am Soc Nephrol. 2011 Jul;6(7):1591-8. Epub 2011 Jun 16.
9. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T,Ronco P. Early-childhood membranous nephropathy due to cationic bovine serumalbumin. N Engl J Med. 2011 Jun 2;364(22):2101-10. Erratum in. N Engl J Med. 2011Aug 4;365(5):477.
10. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z.Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am SocNephrol. 2011 Jun;22(6):1137-43. Epub 2011 May 12.
11. Peces R, Martínez-Ara J, Peces C, Picazo M, Cuesta-López E, Vega C, Azorín S,Selgas R. Nephrotic syndrome and idiopathic membranous nephropathy associatedwith autosomal-dominant polycystic kidney disease. ScientificWorldJournal. 2011May 5;11:1041-7.
12. Meyer-Schwesinger C, Meyer TN, Sievert H, Hoxha E, Sachs M, Klupp EM, MünsterS, Balabanov S, Carrier L, Helmchen U, Thaiss F, Stahl RA. Ubiquitin C-terminalhydrolase-l1 activity induces polyubiquitin accumulation in podocytes andincreases proteinuria in rat membranous nephropathy. Am J Pathol. 2011May;178(5):2044-57.
13. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A₂receptor antibodies correlate with clinical status in idiopathic membranousnephropathy. Clin J Am Soc Nephrol. 2011 Jun;6(6):1286-91. Epub 2011 Apr 7.
14. Chen HW, Chen JS. Multiple thromboembolic events in membranous nephropathy.Intern Med. 2011;50(6):655. Epub 2011 Mar 15.
15. Zhou Q, Zhu K, Yu H, Cheng H. Ichthyosiform mycosis fungoides with alopeciaand atypical membranous nephropathy. Indian J Dermatol Venereol Leprol. 2011Mar-Apr;77(2):180-3.
16. Jefferson JA, Pippin JW, Shankland SJ. Experimental Models of MembranousNephropathy. Drug Discov Today Dis Models. 2010 Spring;7(1-2):27-33.
17. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits inmembranous nephropathy. N Engl J Med. 2011 Feb 17;364(7):689-90.
18. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, DragomirescuL, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S,Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D,Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF,Ronco P, Mathieson PW, Kleta R. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011 Feb 17;364(7):616-26.
19. Sakamaki Y, Hayashi M, Wakino S, Fukuda S, Konishi K, Hashiguchi A, HayashiK, Itoh H. A case of membranous nephropathy with primary biliary cirrhosis andcyclosporine-induced remission. Intern Med. 2011;50(3):233-8. Epub 2011 Feb 1.
20. Wu CC, Chen JS, Huang CF, Chen CC, Lu KC, Chu P, Sytwu HK, Lin YF.Approaching biomarkers of membranous nephropathy from a murine model to humandisease. J Biomed Biotechnol. 2011;2011:581928. Epub 2010 Dec 30.
21. Ito C, Akimoto T, Nakazawa E, Komori S, Sugase T, Chinda J, Takahashi H, IokaT, Muto S, Kusano E. A case of cervical cancer-related membranous nephropathytreated with radiation therapy. Intern Med. 2011;50(1):47-51. Epub 2011 Jan 1.
22. Michel PA, Dahan K, Ancel PY, Plaisier E, Mojaat R, De Seigneux S, Daugas E, Matignon M, Mesnard L, Karras A, François H, Pardon A, Caudwell V, Debiec H,Ronco P. Rituximab treatment for membranous nephropathy. a French clinical andserological retrospective study of 28 patients. Nephron Extra. 2011Jan;1(1):251-61. Epub 2011 Dec 24.
23. Li J, Qu Z, Zhang YM, Yu F, Huang J, Yang R, Zhao MH, Liu G. [Clinicalsignificance of detection of plasma and urine IgG4 in idiopathic membranousnephropathy]. Beijing Da Xue Xue Bao. 2010 Dec 18;42(6):671-4. Chinese.
24. Liu H, Tian N, Arany I, Bigler SA, Waxman DJ, Shah SV, Baliga R. CytochromeP450 2B1 mediates complement-dependent sublytic injury in a model of membranousnephropathy. J Biol Chem. 2010 Dec 24;285(52):40901-10. Epub 2010 Oct 14.
25. Liu YH, Chen CH, Chen SY, Lin YJ, Liao WL, Tsai CH, Wan L, Tsai FJ.Association of phospholipase A2 receptor 1 polymorphisms with idiopathicmembranous nephropathy in Chinese patients in Taiwan. J Biomed Sci. 2010 Oct11;17:81.
26. Stylianou K, Stratakis S, Mavroeidi V, Petrakis I, Xydakis D, Vardaki E,Stratigis S, Perakis K, Katsarou T, Kanellou P, Xylouri I, Petraki C,Alexandrakis M, Daphnis E. Membranous nephropathy and lupus-like syndrome afterhematopoietic cell transplantation. a case report. J Med Case Rep. 2010 Sep10;4:303.
27. Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranousnephropathy after transplantation. N Engl J Med. 2010 Jul 29;363(5):496-8.
28. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, NachmanPH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X,Cattran DC; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy. a 2-year study. Clin J Am Soc Nephrol. 2010Dec;5(12):2188-98. Epub 2010 Aug 12.
29. Patel D, Nivera N, Tunkel AR. Anti-glomerular basement membrane diseasesuperimposed on membranous nephropathy. a case report and review of theliterature. J Med Case Rep. 2010 Aug 2;4:237.
30. Obata Y, Furusu A, Nishino T, Ichinose H, Ohnita A, Iwasaki K, Taguchi T,Kohno S. Membranous nephropathy and Kimura's disease manifesting a hip mass. Acase report with literature review. Intern Med. 2010;49(14):1405-9. Epub 2010 Jul15. Review.
31. Gadonski G, Poli-de-Figueiredo CE, Fervenza FC, Singh AK, Tettamanzy FM,Antonello IC, d'Avila DO. Rapidly deteriorating kidney function in a young manpreviously diagnosed with membranous nephropathy. Nephron Clin Pract.2010;115(2):c100-6. Epub 2010 May 7.
32. Yuan Q, Sun L, Feng J, Liu N, Jiang Y, Ma J, Wang L. Lumbar tuberculosisassociated with membranous nephropathy and interstitial nephritis. J ClinMicrobiol. 2010 Jun;48(6):2303-6. Epub 2010 Apr 7.
33. Glassock RJ. Idiopathic membranous nephropathy. getting better by itself. JAm Soc Nephrol. 2010 Apr;21(4):551-2. Epub 2010 Mar 18.
34. Uramatsu T, Furusu A, Nishino T, Obata Y, Kanamoto Y, Komuro S, Ito M,Taguchi T, Kohno S. Membranous nephropathy complicating nasopharyngeal carcinoma.Intern Med. 2010;49(6):585-8. Epub 2010 Mar 15.
35. Ponticelli C, Passerini P. Can prognostic factors assist therapeuticdecisions in idiopathic membranous nephropathy? J Nephrol. 2010Mar-Apr;23(2):156-63. Review.
36. Nakahara K, Takahashi H, Okuse C, Shigefuku R, Yamada N, Murao M, MatsunagaK, Koike J, Yotsuyanagi H, Suzuki M, Kimura K, Itoh F. Membranous nephropathyassociated with chronic hepatitis B occurring in a short period after acutehepatitis B virus infection. Intern Med. 2010;49(5):383-8. Epub 2010 Mar 1.
37. Ronco P, Debiec H. Antigen identification in membranous nephropathy movestoward targeted monitoring and new therapy. J Am Soc Nephrol. 2010Apr;21(4):564-9. Epub 2010 Feb 25.
38. Sprangers B, Lefkowitz GI, Cohen SD, Stokes MB, Valeri A, Appel GB, Kunis CL.Beneficial effect of rituximab in the treatment of recurrent idiopathicmembranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol. 2010 May;5(5):790-7. Epub 2010 Feb 25.
39. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E,Trivelli A, Magnasco A, Petretto A, Santucci L, Mattei S, Gatti R, Scolari F,Kador P, Allegri L, Ghiggeri GM. Autoimmunity in membranous nephropathy targetsaldose reductase and SOD2. J Am Soc Nephrol. 2010 Mar;21(3):507-19. Epub 2010 Feb11.
40. Hofstra JM, Wetzels JF. Alkylating agents in membranous nephropathy. efficacyproven beyond doubt. Nephrol Dial Transplant. 2010 Jun;25(6):1760-6. Epub 2010Feb 3. Review.
41. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J,Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P,Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F,Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las EnfermedadesGlomerulares de la Sociedad Española de Nefrología. Spontaneous remission ofnephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010Apr;21(4):697-704. Epub 2010 Jan 28.
42. Li SJ, Zhang SH, Chen HP, Zeng CH, Zheng CX, Li LS, Liu ZH. Mercury-inducedmembranous nephropathy. clinical and pathological features. Clin J Am SocNephrol. 2010 Mar;5(3):439-44. Epub 2010 Jan 14.
43. McQuarrie EP, Mackinnon B, Stewart GA, Geddes CC; Scottish Renal BiopsyRegistry. Membranous nephropathy remains the commonest primary cause of nephroticsyndrome in a northern European Caucasian population. Nephrol Dial Transplant.2010 Mar;25(3):1009-10; author reply 1010-1. Epub 2009 Dec 27.
44. Horino T, Nakayama S, Takao T, Terada Y. HLA-B51-related seronegativespondyloarthropathy associated with membranous nephropathy. Rheumatology(Oxford). 2010 Feb;49(2):394-6. Epub 2009 Nov 23.
45. Menon S, Valentini RP. Membranous nephropathy in children. clinicalpresentation and therapeutic approach. Pediatr Nephrol. 2010 Aug;25(8):1419-28.Epub 2009 Nov 12. Review.
46. Prasad D, Khara HS, Gupta M, Sterman P. Celiac disease associated membranous nephropathy - a rare cause or coincidence? A case report. Cases J. 2009 Jun18;2:7018.
47. Soro S, Sánchez de la Nieta MD, Rivera F. [Coeliac disease and membranousnephropathy]. Nefrologia. 2009;29(5):479-81. doi:10.3265/Nefrologia.2009.29.5.5324.en.full. Spanish.
48. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, WetzelsJF. Early versus late start of immunosuppressive therapy in idiopathic membranousnephropathy. a randomized controlled trial. Nephrol Dial Transplant. 2010Jan;25(1):129-36. Epub 2009 Aug 8.
49. Hladunewich MA, Troyanov S, Calafati J, Cattran DC; Metropolitan TorontoGlomerulonephritis Registry. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol. 2009 Sep;4(9):1417-22. Epub 2009 Aug 6.
50. Waldman M, Austin HA 3rd. Controversies in the treatment of idiopathicmembranous nephropathy. Nat Rev Nephrol. 2009 Aug;5(8):469-79. Epub 2009 Jul 7.Review.
51. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathicmembranous nephropathy. N Engl J Med. 2009 Jul 2;361(1):11-21.
52. Yang AH, Lin BS, Kuo KL, Chang CC, Ng YY, Yang WC. The clinicopathologicalimplications of endothelial tubuloreticular inclusions found in glomeruli having histopathology of idiopathic membranous nephropathy. Nephrol Dial Transplant.2009 Nov;24(11):3419-25. Epub 2009 Jun 17.
53. Fervenza FC. Overcoming calcineurin dependence in membranous nephropathy. is rituximab the answer? Clin J Am Soc Nephrol. 2009 Jun;4(6):1017-9. Epub 2009 May 21.
54. Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A. Long-termoutcomes of idiopathic membranous nephropathy in Japanese patients treated withlow-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant. 2009Oct;24(10):3082-8. Epub 2009 May 22.
55. Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. JAm Soc Nephrol. 2009 Apr;20(4):901-11. Epub 2009 Mar 18.
56. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH.Rituximab therapy for membranous nephropathy. a systematic review. Clin J Am Soc Nephrol. 2009 Apr;4(4):734-44. Epub 2009 Mar 11. Review.
57. Lionaki S, Siamopoulos K, Theodorou I, Papadimitraki E, Bertsias G, BoumpasD, Boletis J. Inhibition of tumour necrosis factor alpha in idiopathic membranousnephropathy. a pilot study. Nephrol Dial Transplant. 2009 Jul;24(7):2144-50. Epub2009 Feb 7.
58. Descoeudres B, Giannini O, Aschwanden M, Eugster T, Hopfer H, Mihatsch MJ,Steiger J, Mayr M. Silent recovery of native kidney function aftertransplantation in a patient with membranous nephropathy. Nephrol DialTransplant. 2009 Apr;24(4):1345-9. Epub 2009 Jan 22.
59. Majoni SW, Smith SR. Membranous nephropathy in a patient with hereditaryangioedema. a case report. J Med Case Rep. 2008 Oct 13;2:328.
60. Peña Porta JM, González Igual J, de Vera Floristán CV. [Autoimmunethyroiditis, subclinical hypothyroidism, and nephrotic syndrome caused bymembranous nephropathy]. Nefrologia. 2008;28(5):572-3. Spanish.
61. Hofstra JM, Wetzels JF. Introduction of a cyclophosphamide-based treatmentstrategy and the risk of ESRD in patients with idiopathic membranous nephropathy:a nationwide survey in the Netherlands. Nephrol Dial Transplant. 2008Nov;23(11):3534-8. Epub 2008 Jun 17.
62. Chen CH, Shu KH, Wen MC, Chen KJ, Cheng CH, Lian JD, Wu MJ, Yu TM, Tsai FJ.Impact of plasminogen activator inhibitor-1 gene polymorphisms on primarymembranous nephropathy. Nephrol Dial Transplant. 2008 Oct;23(10):3166-73. Epub2008 May 21.
63. Makino M, Honda H, Miyoshi F, Ban Y, Katagiri T, Matsuyama TA, Ota H,Yoshitake O, Kusano M, Shibata T, Akizawa T. A fulminant case of renal veinthrombosis in a patient with autoimmune disorder and membranous nephropathy.Intern Med. 2008;47(10):969-73. Epub 2008 May 15.
64. Wu CC, Lu KC, Chen JS, Hsieh HY, Lin SH, Chu P, Wang JY, Sytwu HK, Lin YF.HO-1 induction ameliorates experimental murine membranous nephropathy:anti-oxidative, anti-apoptotic and immunomodulatory effects. Nephrol DialTransplant. 2008 Oct;23(10):3082-90. Epub 2008 May 12.
65. Prabahar MR, Jayakumar M, Soundararajan P. Chronic inferior venacavathrombosis in membranous nephropathy. Nephrol Dial Transplant. 2008Jul;23(7):2422-3. Epub 2008 May 2.
66. Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF. Urinary excretion offatty acid-binding proteins in idiopathic membranous nephropathy. Nephrol DialTransplant. 2008 Oct;23(10):3160-5. Epub 2008 Apr 10.
67. Ferrannini M, Vischini G, Di Daniele N. Rituximab in membranous nephropathyafter haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2008Aug;23(8):2700-1; author reply 2701. Epub 2008 Apr 2.
68. Hofstra JM, Deegens JK, Willems HL, Wetzels JF. Beta-2-microglobulin issuperior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathicmembranous nephropathy. Nephrol Dial Transplant. 2008 Aug;23(8):2546-51. Epub2008 Feb 28.
69. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy. diagnosis and treatment. Clin J Am Soc Nephrol. 2008 May;3(3):905-19. Epub 2008 Jan 30.
70. Passerini P, Ponticelli C. Treatment of membranous nephropathy. Saudi JKidney Dis Transpl. 2000 Jul-Sep;11(3):345-52.
71. Rico J, Cardona MX, Vanegas J, López R. [Membranous nephropathy presenting asmicroscopic hematuria]. Nefrologia. 2007;27(5):647-8. Spanish.
72. Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, SakhujaV, Jha V. Mycophenolate mofetil or standard therapy for membranous nephropathyand focal segmental glomerulosclerosis. a pilot study. Nephrol Dial Transplant.2008 Jun;23(6):1926-30. Epub 2007 Nov 7.
73. Martín-Penagos L, Fernández Fresnedo G, Sanz de Castro S, Arias M. [Colonadenocarcinoma after spontaneous remission of membranous nephropathy].Nefrologia. 2007;27(4):516. Spanish.
74. Kimura M, Toyoda M, Kobayashi K, Abe M, Kobayashi T, Kato M, Miyauchi M,Yamamoto N, Maruyama M, Umezono T, Nishina M, Yagame M, Endo M, Suzuki D. Aretrospective study on the efficacy of corticosteroid-alone therapy in membranousnephropathy patients. Intern Med. 2007;46(19):1641-5. Epub 2007 Oct 1.
75. Sugimoto T, Furukawa T, Maeda T, Somura M, Uzu T, Kashiwagi A. Markedreduction of proteinuria after eradication of gastric Helicobacter pyloriinfection in a patient with membranous nephropathy. coincidental or associated?Intern Med. 2007;46(17):1483-4. Epub 2007 Sep 3.
76. Yamada H, Miura N, Kitagawa W, Kashima Y, Matsui S, Ozeki N, Nishikawa K,Imai H. Membranous nephropathy and pulmonary alveolar proteinosis. Intern Med.2007;46(17):1441-6. Epub 2007 Sep 3.
77. Tao JL, Li H, Wen YB, Li XW. Idiopathic membranous nephropathy complicatedwith malignant hypertension. a case report. Chin Med J (Engl). 2007 Aug5;120(15):1369-71.
78. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M,Remuzzi G. Rituximab for idiopathic membranous nephropathy. who can benefit? ClinJ Am Soc Nephrol. 2006 Jul;1(4):738-48. Epub 2006 Jun 14.
79. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab tocirculating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007 Sep;2(5):932-7. Epub 2007 Aug 16.
80. Pansini F, Bonifati C, Manno C, Schena FP. Rituximab induces completeremission in a case of membranous nephropathy associated with hepatitis C virus- related infection. Nephrol Dial Transplant. 2007 Dec;22(12):3674-6. Epub 2007 Aug8.
81. Chen A, Frank R, Vento S, Crosby V, Chandra M, Gauthier B, Valderrama E,Trachtman H. Idiopathic membranous nephropathy in pediatric patients:presentation, response to therapy, and long-term outcome. BMC Nephrol. 2007 Aug6;8:11.
82. Sugimoto T, Aoyama M, Kikuchi K, Sakaguchi M, Deji N, Uzu T, Nishio Y,Kashiwagi A. Membranous nephropathy associated with the relatively selectivecyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoidarthritis. Intern Med. 2007;46(13):1055-8. Epub 2007 Jul 2.
83. Sugimoto T, Tanaka Y, Sakaguchi M, Osawa N, Tanaka Y, Uzu T, Kashiwagi A. Acase of post-allogeneic haematopoietic stem cell transplantation membranousnephropathy. Nephrol Dial Transplant. 2007 Nov;22(11):3362-3. Epub 2007 Jun 30.
84. Ballarin J, Poveda R, Ara J, Pérez L, Calero F, Grinyó JM, Romero R.Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil. results of a pilot study. Nephrol DialTransplant. 2007 Nov;22(11):3196-201. Epub 2007 Jun 25.
85. Ponticelli C. Membranous nephropathy. J Nephrol. 2007 May-Jun;20(3):268-87.Review.
86. Matsumoto Y, Lee C, Shimada S. Effective treatment of four consecutiveidiopathic membranous nephropathy patients. Nephrol Dial Transplant. 2007Sep;22(9):2726-7. Epub 2007 Jun 2.
87. Izzedine H, Brocheriou I, Becart J, Deray G. Probenecid-induced membranousnephropathy. Nephrol Dial Transplant. 2007 Aug;22(8):2405-6. Epub 2007 May 17.
88. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V. Arandomized, controlled trial of steroids and cyclophosphamide in adults withnephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol.2007 Jun;18(6):1899-904. Epub 2007 May 9.
89. Heeringa SF, Branten AJ, Deegens JK, Steenbergen E, Wetzels JF. Focalsegmental glomerulosclerosis is not a sufficient predictor of renal outcome inpatients with membranous nephropathy. Nephrol Dial Transplant. 2007Aug;22(8):2201-7. Epub 2007 Apr 18.
90. Terrier B, Delmas Y, Hummel A, Presne C, Glowacki F, Knebelmann B, Combe C,Lesavre P, Maillard N, Noël LH, Patey-Mariaud de Serre N, Nusbaum S, Radford I,Buzyn A, Fakhouri F. Post-allogeneic haematopoietic stem cell transplantationmembranous nephropathy. clinical presentation, outcome and pathogenic aspects.Nephrol Dial Transplant. 2007 May;22(5):1369-76. Epub 2007 Jan 25.
91. Fujita T, Nakamura N, Kumasaka R, Shimada M, Murakami R, Osawa H, Yamabe H,Okumura K. Comparison of lipid and fatty acid metabolism between minimal changenephrotic syndrome and membranous nephropathy. In Vivo. 2006Nov-Dec;20(6B):891-3.
92. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D.Induction and long-term treatment with cyclosporine in membranous nephropathywith the nephrotic syndrome. Nephrol Dial Transplant. 2006 Nov;21(11):3127-32.Epub 2006 Sep 12.
93. Ronco P, Debiec H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy. towards epitope-driven therapies. J Am Soc Nephrol. 2006 Jul;17(7):1772-4. Epub 2006 Jun 14.
94. Nishioka Y, Horita Y, Tadokoro M, Taura K, Suyama N, Miyazaki M, Harada T,Kohno S. Changing mizoribine administration from three divided doses to onesingle dose induced remission of relapsed membranous nephropathy. Nephrol DialTransplant. 2006 Aug;21(8):2337-8. Epub 2006 Mar 17.
95. du Buf-Vereijken PW, Wetzels JF. Treatment-related changes in urinaryexcretion of high and low molecular weight proteins in patients with idiopathicmembranous nephropathy and renal insufficiency. Nephrol Dial Transplant. 2006Feb;21(2):389-96. Epub 2005 Oct 18.
96. Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol. 2005 Oct;289(4):F660-71. Review.
97. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W.Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol. 2005Jul;16(7):2063-72. Epub 2005 May 25.
98. Ardiles L, Blackburn E, Alruiz P, Flores C, Mezzano S. [Antiphospholipidantibodies in idiopathic membranous nephropathy]. Rev Med Chil. 2005Mar;133(3):287-93. Epub 2005 May 5. Spanish.
99. Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy. from Heymann nephritis to alloimmunization. J Am Soc Nephrol. 2005 May;16(5):1205-13. Epub 2005 Mar 30. Review.
100. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury inmembranous nephropathy. J Am Soc Nephrol. 2005 May;16(5):1195-204. Epub 2005 Mar 30. Review.
101. Cattran D. Management of membranous nephropathy. when and what fortreatment. J Am Soc Nephrol. 2005 May;16(5):1188-94. Epub 2005 Mar 30. Review.
102. Couser WG. Membranous nephropathy. a long road but well traveled. J Am SocNephrol. 2005 May;16(5):1184-7. Epub 2005 Mar 30. Review.
103. Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol. 2005 May;16(5):1214-22.Epub 2005 Mar 30. Review.
104. Rossi P, Demoux AL, Granel B, Bagnères D, Bonin-Guillaume S, Frances Y.Anti-CD20 monoclonal antibody for the treatment of refractory autoimmunehaemolytic anaemia associated with idiopathic membranous nephropathy.Rheumatology (Oxford). 2005 Mar;44(3):403-5. Epub 2005 Jan 5.
105. Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW, HollanderDA, Wetzels JF. Urinary excretion of beta2-microglobulin and IgG predictprognosis in idiopathic membranous nephropathy. a validation study. J Am SocNephrol. 2005 Jan;16(1):169-74. Epub 2004 Nov 24.
106. Chen JS, Chen A, Chang LC, Chang WS, Lee HS, Lin SH, Lin YF. Mouse model of membranous nephropathy induced by cationic bovine serum albumin. antigendose-response relations and strain differences. Nephrol Dial Transplant. 2004Nov;19(11):2721-8. Epub 2004 Sep 22.
107. du Buf-Vereijken PW, Wetzels JF. Efficacy of a second course ofimmunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant. 2004 Aug;19(8):2036-43.Epub 2004 Jun 8.
108. du Buf-Vereijken PW, Feith GW, Hollander D, Gerlag PG, Wirtz JJ, NoordzijTC, Wetzels JF; Membranous Nephropathy Study Group. Restrictive use ofimmunosuppressive treatment in patients with idiopathic membranous nephropathy:high renal survival in a large patient cohort. QJM. 2004 Jun;97(6):353-60.
109. Lhotta K, Würzner R, Rumpelt HJ, Eder P, Mayer G. Membranous nephropathy in a patient with hereditary complete complement C4 deficiency. Nephrol DialTransplant. 2004 Apr;19(4):990-3.
110. du Buf-Vereijken PW, Branten AJ, Wetzels JF; Membranous Nephropathy StudyGroup. Cytotoxic therapy for membranous nephropathy and renal insufficiency:improved renal survival but high relapse rate. Nephrol Dial Transplant. 2004May;19(5):1142-8. Epub 2004 Feb 19.
111. Fujimoto S, Hara S, Sato Y, Yamada K, Hisanaga S, Eto T. Nephrotic syndrome caused by membranous nephropathy. response to a short course of cyclophosphamide alternating with prednisolone. Intern Med. 2004 Jan;43(1):30-4.
112. Masutani K, Taniguchi M, Nakashima H, Yotsueda H, Kudoh Y, Tsuruya K,Tokumoto M, Fukuda K, Kanai H, Hirakata H, Iida M. Up-regulated interleukin-4production by peripheral T-helper cells in idiopathic membranous nephropathy.Nephrol Dial Transplant. 2004 Mar;19(3):580-6.
113. Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, Kigawa A, SawadaK, Imai H. Distribution of glomerular IgG subclass deposits inmalignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004Mar;19(3):574-9.
114. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, RemuzziG. Rituximab in idiopathic membranous nephropathy. a one-year prospective study. J Am Soc Nephrol. 2003 Jul;14(7):1851-7.
115. Razukeviciene L, Kuzminskis V, Bumblyte IA, Laurinavicius A. [Prognosis ofchronic renal failure in patients with membranous nephropathy]. Medicina(Kaunas). 2003;39 Suppl 1:9-15. Lithuanian.
116. Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant. 2003Jun;18(6):1233-4.
117. Kim KW, Yoon CH, Kay CS, Kim HJ, Suh KS, Kim SY, Park SY. Membranousnephropathy after allogeneic hematopoietic stem cell transplantation in a patientwith aplastic anemia. a case report. J Korean Med Sci. 2003 Apr;18(2):287-9.
118. Hladunewich MA, Lemley KV, Blouch KL, Myers BD. Determinants of GFRdepression in early membranous nephropathy. Am J Physiol Renal Physiol. 2003May;284(5):F1014-22. Epub 2003 Jan 14.
119. Kuroki A, Shibata T, Honda H, Totsuka D, Kobayashi K, Sugisaki T. Glomerularand serum IgG subclasses in diffuse proliferative lupus nephritis, membranouslupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002Nov;41(11):936-42.
120. Kolasinski SL, Chung JB, Albert DA. What do we know about lupus membranousnephropathy? An analytic review. Arthritis Rheum. 2002 Aug;47(4):450-5. Review.
121. Apostolou T, Sotsiou F, Pappas C, Rontoianni D, Apostolidis J, Nikolopoulou N. Atheroembolic renal disease and membranous nephropathy, in a patient withmyelodysplastic syndrome, eosinophilia, and trisomy 8. Nephrol Dial Transplant.2002 Jul;17(7):1336-8.
122. Bazzi C, D'Amico G. The urinary excretion of IgG and alpha1-microglobulinpredicts renal outcome and identifies patients deserving treatment in membranous nephropathy. Kidney Int. 2002 Jun;61(6):2276.
123. Bhimma R, Hammond MG, Coovadia HM, Adhikari M, Connolly CA. HLA class I and II in black children with hepatitis B virus-associated membranous nephropathy.Kidney Int. 2002 Apr;61(4):1510-5.
124. Yuan H, Takeuchi E, Taylor GA, McLaughlin M, Brown D, Salant DJ. Nephrindissociates from actin, and its expression is reduced in early experimentalmembranous nephropathy. J Am Soc Nephrol. 2002 Apr;13(4):946-56.
125. Shirota S, Tsuchiya K, Takada M, Komeda M, Oomae K, Ogawa T, Yumura W, NittaK, Nihei H. Retroperitoneal fibrosis associated with membranous nephropathyeffectively treated with steroids. Intern Med. 2002 Jan;41(1):20-5. Review.
126. Alagözlü H, Candan F, Gültekin F, Bulut E, Elagoz S. Horseshoe kidney andnephrotic syndrome due to idiopathic membranous nephropathy. Intern Med. 2001Dec;40(12):1259-60.
127. Yao X, Chen H, Wang Q, Tang Z, Hu W, Yin G, Liu Z, Li L. Cyclosporin Atreatment for idiopathic membranous nephropathy. Chin Med J (Engl). 2001Dec;114(12):1305-8.
128. Cattran DC. Membranous nephropathy. quo vadis? Kidney Int. 2002Jan;61(1):349-50. Review.
129. Torres A, Domínguez-Gil B, Carreño A, Hernández E, Morales E, Segura J,González E, Praga M. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002 Jan;61(1):219-27.
130. Miyazaki K, Miyazaki M, Tsurutani H, Sasaki O, Furusu A, Taguchi T, HaradaT, Ozono Y, Kohno S. Development of IgA nephropathy 14 years after diagnosis ofmembranous nephropathy. Nephrol Dial Transplant. 2002 Jan;17(1):140-3.
131. Papagianni AA, Alexopoulos E, Leontsini M, Papadimitriou M. C5b-9 andadhesion molecules in human idiopathic membranous nephropathy. Nephrol DialTransplant. 2002 Jan;17(1):57-63.
132. Aymaz S, Gross O, Krakamp B, Ortmann M, Dienes HP, Weber M. Membranousnephropathy from exposure to mercury in the fluorescent-tube-recycling industry. Nephrol Dial Transplant. 2001 Nov;16(11):2253-5.
133. Ponticelli C, Passerini P. Treatment of membranous nephropathy. Nephrol DialTransplant. 2001;16 Suppl 5:8-10. Review.
134. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy. a randomized trial. Kidney Int.2001 Apr;59(4):1484-90.
135. Arnadottir M, Hultberg B, Berg AL. Plasma total homocysteine concentrationin nephrotic patients with idiopathic membranous nephropathy. Nephrol DialTransplant. 2001 Jan;16(1):45-7.
136. Gradden CW, Pai P, Hindell P, O'Donoghue DJ, Mason H, Bell GM. Membranousnephropathy, hydrocarbon exposure and genetic variants of hydrocarbondetoxification. QJM. 2001 Feb;94(2):79-87.
137. Sano T, Kamata K, Shigematsu H, Kobayashi Y. A case of anti-glomerularbasement membrane glomerulonephritis superimposed on membranous nephropathy.Nephrol Dial Transplant. 2000 Aug;15(8):1238-41.
138. Matsuda M, Miki J, Tabata K, Ikezoe M, Nishizawa N, Ishigame H. Myastheniagravis with membranous nephropathy, successfully treated with extended totalthymectomy. Intern Med. 2000 Jun;39(6):490-4.
139. Shankland SJ. New insights into the pathogenesis of membranous nephropathy. Kidney Int. 2000 Mar;57(3):1204-5. Review.
140. Cybulsky AV, Takano T, Papillon J, McTavish AJ. Complement-inducedphospholipase A2 activation in experimental membranous nephropathy. Kidney Int.2000 Mar;57(3):1052-62.
141. Matsuda K, Masaki T, Ishii S, Yamashita H, Watanabe T, Nagawa H, Muto T,Hirata Y, Kimura K, Kojima S. Possible associations of rectal carcinoma withSchistosoma japonicum infection and membranous nephropathy. a case report with a review. Jpn J Clin Oncol. 1999 Nov;29(11):576-81. Review.
142. Tang S, Chan TM, Cheng IK, Lai KN. Clinical features and treatment outcomeof idiopathic membranous nephropathy in Chinese patients. QJM. 1999Jul;92(7):401-6.
143. Mezzano SA, Droguett MA, Burgos ME, Ardiles LG, Aros CA, Caorsi I, Egido J. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in humanmembranous nephropathy. Kidney Int. 2000 Jan;57(1):147-58.
144. Montinaro V, Lopez A, Monno R, Cappiello V, Manno C, Gesualdo L, Schena FP. Renal C3 synthesis in idiopathic membranous nephropathy. correlation to urinaryC5b-9 excretion. Kidney Int. 2000 Jan;57(1):137-46.
145. Wakui H, Imai H, Komatsuda A, Miura AB. Circulating antibodies againstalpha-enolase in patients with primary membranous nephropathy (MN). Clin ExpImmunol. 1999 Dec;118(3):445-50.
146. Levy Y, Sherer Y, George J, Fabbrizzi F, Shoenfeld Y. Use of intravenousimmunoglobulin in idiopathic membranous nephropathy. Intern Med. 1999Nov;38(11):917.
147. Toda T, Kimoto S, Nishio Y, Ehara T, Sasaki S. Sarcoidosis with membranousnephropathy and granulomatous interstitial nephritis. Intern Med. 1999Nov;38(11):882-6.
148. Yokoyama H, Goshima S, Wada T, Takaeda M, Furuichi K, Kobayashi K, Kida H.The short- and long-term outcomes of membranous nephropathy treated withintravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant. 1999 Oct;14(10):2379-86.
149. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on theserum lipoprotein profile and glomerular function in patients with membranousnephropathy. Kidney Int. 1999 Oct;56(4):1534-43.
150. Marx BE, Marx M. Prediction in idiopathic membranous nephropathy. KidneyInt. 1999 Aug;56(2):666-73.
151. Bhimma R, Coovadia HM, Kramvis A, Adhikari M, Kew MC, Connolly CA. HBV andproteinuria in relatives and contacts of children with hepatitis Bvirus-associated membranous nephropathy. Kidney Int. 1999 Jun;55(6):2440-9.
152. Moroni G, Faricciotti A, Cappelletti M, Ponticelli C. Retroperitonealfibrosis and membranous nephropathy. Improvement of both diseases after treatmentwith steroids and immunosuppressive agents. Nephrol Dial Transplant. 1999May;14(5):1303-5. Erratum in. Nephrol Dial Transplant. 2007 May;22(5):1491.Farricciotti, A [corrected to Faricciotti, A].
153. Gonzalo A, Mampaso F, Bárcena R, Gallego N, Ortuño J. Membranous nephropathyassociated with hepatitis B virus infection. long-term clinical and histological outcome. Nephrol Dial Transplant. 1999 Feb;14(2):416-8.
154. Ponticelli C, Villa M. Does cyclosporin have a role in the treatment ofmembranous nephropathy? Nephrol Dial Transplant. 1999 Jan;14(1):23-5. Review.
155. Tatsumi H, Tateno S, Hiki Y, Shigematsu H, Kobayashi Y. Crescenticglomerulonephritis associated with membranous nephropathy in a case with primary Sjögren's syndrome. Nephrol Dial Transplant. 1998 Oct;13(10):2624-7.
156. Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renalinsufficiency. QJM. 1998 May;91(5):359-66.
157. Squarer A, Lemley KV, Ambalavanan S, Kristal B, Deen WM, Sibley R, Anderson L, Myers BD. Mechanisms of progressive glomerular injury in membranousnephropathy. J Am Soc Nephrol. 1998 Aug;9(8):1389-98.
158. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats withmembranous nephropathy. Kidney Int. 1998 Aug;54(2):353-9.
159. Dienstl A, Lhotta K, König P, Pechlaner C, Wiedermann CJ, Joannidis M.Pulmonary haemorrhage in a patient with idiopathic membranous nephropathy.Nephrol Dial Transplant. 1998 Jul;13(7):1815-7.
160. Stirling CM, Simpson K, Boulton-Jones JM. Immunosuppression and outcome inidiopathic membranous nephropathy. QJM. 1998 Feb;91(2):159-64.
161. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B,Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, FarinaM, Bellazzi R. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranousnephropathy. J Am Soc Nephrol. 1998 Mar;9(3):444-50.
162. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ. Circulating factors insera or peripheral blood mononuclear cells in patients with membranousnephropathy or diabetic nephropathy. J Korean Med Sci. 1997 Dec;12(6):539-44.
163. Kanahara K, Yorioka N, Nakamura C, Kyuden Y, Ogata S, Taguchi T, Yamakido M.Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritiswith membranous nephropathy in remission. Intern Med. 1997 Nov;36(11):841-6.
164. Allegri L. Antigens in experimental models of membranous nephropathy. arethey involved in human disease? Nephrol Dial Transplant. 1997 Sep;12(9):1801-4.Review.
165. Tse WY, Howie AJ, Adu D, Savage CO, Richards NT, Wheeler DC, Michael J.Association of vasculitic glomerulonephritis with membranous nephropathy. areport of 10 cases. Nephrol Dial Transplant. 1997 May;12(5):1017-27. Review.
166. Roberts IS, Burrows C, Shanks JH, Venning M, McWilliam LJ. Interstitialmyofibroblasts. predictors of progression in membranous nephropathy. J ClinPathol. 1997 Feb;50(2):123-7.
167. Jeremiah P, Mackenzie P, Fox JG, Mactier RA, Ingram S, Moss J. Acuteinferior vena cava thrombosis in a patient with membranous nephropathy treated byrt-PA lysis. Nephrol Dial Transplant. 1997 Jan;12(1):195-7.
168. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in ratexperimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol. 1996Dec;7(12):2518-26. Review.
169. Nakamura T, Tanaka N, Higuma N, Kazama T, Kobayashi I, Yokota S. Thelocalization of plasminogen activator inhibitor-1 in glomerular subepithelialdeposits in membranous nephropathy. J Am Soc Nephrol. 1996 Nov;7(11):2434-44.
170. Crowe AV, Raman GV, Turner AM. Membranous nephropathy associated with aninflammatory myelopathy. Nephrol Dial Transplant. 1996 Aug;11(8):1625-6.
171. Irie F, Kobayashi M, Hirayama K, Nagase S, Iitsuka T, Yamaguchi N, Koyama A.Rheumatoid arthritis associated with membranous nephropathy and IgA nephritiswith necrotizing lesions. Nephrol Dial Transplant. 1996 Jul;11(7):1338-41.Review.
172. Marcen R, Mampaso F, Teruel JL, Rivera ME, Orofino L, Navarro-Antolin J,Ortuño J. Membranous nephropathy. recurrence after kidney transplantation.Nephrol Dial Transplant. 1996 Jun;11(6):1129-33.
173. Mathieson PW, Peat DS, Short A, Watts RA. Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association withpenicillamine. Nephrol Dial Transplant. 1996 May;11(5):863-6. Review.
174. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9with enhanced expression in a model of membranous nephropathy. J Clin Invest.1996 Feb 15;97(4):1094-101.
175. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. Mechanism of theantiproteinuric effect of cyclosporine in membranous nephropathy. J Am SocNephrol. 1996 Feb;7(2):290-8.
176. Reichert LJ, Koene RA, Wetzels JF. Urinary excretion of beta 2-microglobulinpredicts renal outcome in patients with idiopathic membranous nephropathy. J AmSoc Nephrol. 1995 Dec;6(6):1666-9.
177. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, Couser WG,Koch KM. Basic fibroblast growth factor augments podocyte injury and inducesglomerulosclerosis in rats with experimental membranous nephropathy. J ClinInvest. 1995 Dec;96(6):2809-19.
178. Coers W, Vos JT, Van der Meide PH, Van der Horst ML, Huitema S, Weening JJ. Interferon-gamma (IFN-gamma) and IL-4 expressed during mercury-induced membranousnephropathy are toxic for cultured podocytes. Clin Exp Immunol. 1995Nov;102(2):297-307.
179. Sims S, Rotellar C. Therapy of membranous nephropathy. use of low-proteindiet. J Am Soc Nephrol. 1995 Jul;6(1):136-7.
180. Neale TJ, Rüger BM, Macaulay H, Dunbar PR, Hasan Q, Bourke A,Murray-McIntosh RP, Kitching AR. Tumor necrosis factor-alpha is expressed byglomerular visceral epithelial cells in human membranous nephropathy. Am JPathol. 1995 Jun;146(6):1444-54.
181. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial inidiopathic membranous nephropathy? A meta-analysis of the controlled trials. J AmSoc Nephrol. 1995 Feb;5(8):1553-8.
182. Hebert LA. Therapy of membranous nephropathy. what to do after the after(meta) analyses. J Am Soc Nephrol. 1995 Feb;5(8):1543-5.
183. Chevrier D, Giral M, Braud V, Soulillou JP, Bignon JD. Membranousnephropathy and a TAP1 gene polymorphism. N Engl J Med. 1994 Jul 14;331(2):133-4.
184. Cavallo T. Membranous nephropathy. Insights from Heymann nephritis. Am JPathol. 1994 Apr;144(4):651-8. Review.
185. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, RemuzziG. Prognosis of untreated patients with idiopathic membranous nephropathy. N EnglJ Med. 1993 Jul 8;329(2):85-9.
186. Chaturvedi S. Fulminant cerebral infarctions with membranous nephropathy.Stroke. 1993 Mar;24(3):473-5.
187. Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone pluschlorambucil as compared with methylprednisolone alone for the treatment ofidiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med. 1992 Aug 27;327(9):599-603.
188. Tattersall J, Greenwood R, Farrington K. Membranous nephropathy associatedwith diclofenac. Postgrad Med J. 1992 May;68(799):392-3.
189. Kim Y, Butkowski R, Burke B, Kleppel MM, Crosson J, Katz A, Michael AF.Differential expression of basement membrane collagen in membranous nephropathy. Am J Pathol. 1991 Dec;139(6):1381-8.
190. Lai KN, Li PK, Lui SF, Au TC, Tam JS, Tong KL, Lai FM. Membranousnephropathy related to hepatitis B virus in adults. N Engl J Med. 1991 May23;324(21):1457-63.
191. Lai KN, Lo ST, Lai FM. Immunohistochemical study of the membrane attackcomplex of complement and S-protein in idiopathic and secondary membranousnephropathy. Am J Pathol. 1989 Sep;135(3):469-76. Erratum in. Am J Pathol 1989Dec;135(6):followi.
192. Baker PJ, Ochi RF, Schulze M, Johnson RJ, Campbell C, Couser WG. Depletionof C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol. 1989 Jul;135(1):185-94.
193. Oliveira DB, Foster G, Savill J, Syme PD, Taylor A. Membranous nephropathycaused by mercury-containing skin lightening cream. Postgrad Med J. 1987Apr;63(738):303-4.
194. Jaenke RS, Allen TA. Membranous nephropathy in the dog. Vet Pathol. 1986Nov;23(6):718-33.
195. Cybulsky AV, Rennke HG, Feintzeig ID, Salant DJ. Complement-inducedglomerular epithelial cell injury. Role of the membrane attack complex in ratmembranous nephropathy. J Clin Invest. 1986 Apr;77(4):1096-107.
196. Feehally J, Brenchley PE, Coupes BM, Mallick NP, Morris DM, Short CD.Impaired IgG response to tetanus toxoid in human membranous nephropathy:association with HLA-DR3. Clin Exp Immunol. 1986 Feb;63(2):376-84.
197. Short CD, Feehally J, Gokal R, Mallick NP. Familial membranous nephropathy. Br Med J (Clin Res Ed). 1984 Dec 1;289(6457):1500.
198. Doi T, Mayumi M, Kanatsu K, Suehiro F, Hamashima Y. Distribution of IgGsubclasses in membranous nephropathy. Clin Exp Immunol. 1984 Oct;58(1):57-62.
199. McGinley E, Martin W, Henderson N, Boulton-Jones JM. Defective splenicreticuloendothelial function in idiopathic membranous nephropathy. Clin ExpImmunol. 1984 May;56(2):295-301.
200. Groggel GC, Adler S, Rennke HG, Couser WG, Salant DJ. Role of the terminalcomplement pathway in experimental membranous nephropathy in the rabbit. J ClinInvest. 1983 Dec;72(6):1948-57.
201. Adler SG, Wang H, Ward HJ, Cohen AH, Border WA. Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. J Clin Invest. 1983 Mar;71(3):487-99.
202. Border WA, Ward HJ, Kamil ES, Cohen AH. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest.1982 Feb;69(2):451-61.
203. Iwaoka T, Umeda T, Nakayama M, Shimada T, Fujii Y, Miura F, Sato T. A caseof membranous nephropathy associated with thyroid antigens. Jpn J Med. 1982Jan;21(1):29-34.
204. Hopper J Jr, Biava CG, Tu WH. Membranous nephropathy. high-dosealternate-day therapy with prednisone. West J Med. 1981 Jul;135(1):1-8.
205. Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement inexperimental membranous nephropathy in rats. J Clin Invest. 1980Dec;66(6):1339-50.
206. Friend PS, Kim Y, Michael AF, Donadio JV. Pathogenesis of membranousnephropathy in systemic lupus erythematosus. possible role of nonprecipitatingDNA antibody. Br Med J. 1977 Jan 1;1(6052):25.
207. Kibukamusoke JW, Davies DR, Hutt MS. Membranous nephropathy due toskin-lightening cream. Br Med J. 1974 Jun 22;2(5920):646-7.